Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 268

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 268
---
 class.

Alteration of Share Capital and Repurchases

Subject to the provisions
of the Companies Act, and without prejudice to any relevant special rights attached to any class of shares, we may, from time to time:

| · | increase our share capital by allotting and issuing new shares in accordance with the our articles of 
 association and any relevant shareholder resolution;                                                  |

| · | consolidate all or any of our share capital into shares of a larger nominal amount (i.e., par value) than 
 the existing shares;                                                                                      |

| · | subdivide any of our shares into shares of a smaller nominal amount (i.e., par value) than our existing 
 shares; or                                                                                              |

| · | redenominate our share capital or any class of share capital. |

Preemptive Rights and New Issuance of Shares

Under the Companies Act, the
issuance of equity securities (except shares held under an employees’ share scheme) that are to be paid for wholly in cash must
be offered first to the existing holders of equity securities in proportion to the respective nominal amounts (i.e., par values) of their
holdings on the same or more favorable terms, unless a special resolution to the contrary has been passed or the articles of association
otherwise provide an exclusion from this requirement (which exclusion can be for a maximum of five years after which our shareholders’
approval would be required to renew the exclusion). In this context, “equity securities” means ordinary shares (and would
exclude shares that, with respect to dividends or capital, carry a right to participate only up to a specified amount in a distribution),
and any and all rights to subscribe for or convert securities into such ordinary shares. This differs from U.S. law, under which shareholders
generally do not have pre-emptive rights unless specifically granted in the certificate of incorporation or otherwise.

The Board seeks general authority to allot shares on a non-pre-emptive basis at each annual general meeting. By way of resolutions passed at our annual general meeting held on June 14, 2023, authorities were given to the directors to generally allot shares in the Company, or to grant rights to subscribe for or to convert or exchange any security into shares in the Company, up to an aggregate nominal amount of £140,000,000, for a period up to the conclusion of our annual general meeting to be held in 2026. At our annual general meeting held on June 13, 2024, authorities were given